A Multicenter, Open-Label Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-Line Systemic Atezolizumab Plus Bevacizumab in Patients with Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma (HCC).
Journal of Clinical Oncology（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要